세계의 바이러스 백신 시장 예측(-2030년) : 유형별, 형태별, 용기 형태별, 생물학적 안전성 수준 유형별, 기술별, 질병별, 투여 연령별, 투여 경로별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Viral Vaccines Market is accounted for $100.57 billion in 2023 and is expected to reach $148.25 billion by 2030 growing at a CAGR of 5.7% during the forecast period. Viral vaccines are considered one of the most effective prevention measures against viral infections caused by viral agents. Along with other serious viral infections including the human immunodeficiency virus (HIV/AIDS), Ebola, influenza, COVID-19, and many others, viruses also cause a number of well-known infectious diseases, including the common cold, flu, and warts. The prevalence of various viral infections varies globally by region, season, and even day of the week. As a result, there is a variable need for these medications.

According to WHO, 325 million people, or roughly 4% of the world's population, live with viral hepatitis and the disease causes 1.34 million deaths per year

Market Dynamics:

Driver:

Infectious diseases are growing more widespread and were re-emerging

Living in more densely populated places, traveling much more frequently and over longer distances than in the past, and increasing human-wildlife contact raise serious concerns about the potential for new infectious diseases to spread quickly and trigger pandemics over the world. Additionally, there's a chance that diseases could spread as a result of intentional introduction into communities of people, animals, or plants for terrorist goals. About 40 infectious diseases, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and most recently COVID-19, have been identified. Future pandemics and epidemics will be much deadlier than COVID-19, experts have warned.

Restraint:

High cost of vaccine development

The process of developing vaccines requires a significant amount of capital. The cost of storing and shipping vaccinations is higher than that of any other pharmaceutical product because they need specific facilities and monitoring systems. The effectiveness and quality of vaccines can suffer from inadequate storage and delivery infrastructure. From in vitro research to marketing, the development process takes 10 to 15 years and costs between US$800 million and US$1 billion. Additionally, because vaccine research has a poor success rate, businesses struggle to control operational expenses and secure initial investments. Therefore, the high cost of vaccine production and storage is limiting market expansion.

Opportunity:

High growth prospects in emerging markets

Due to the rising patient populations and disposable incomes, emerging regions like China, India, and Southeast Asia present expanding potential for the vaccination industry. Major market firms have been enticed to invest in these economies by their development potential. The development of low-cost, accessible vaccinations is another area in which businesses are investing and concentrating in order to expand the reach of immunization programs in these economies.

Threat:

Inequitable access to vaccines

Inequitable access to vaccines poses a significant threat to the viral vaccines market. The global distribution and availability of vaccines are crucial for combating infectious diseases and ensuring public health. However, when access to vaccines is unevenly distributed across countries and populations, it hinders the effectiveness of vaccination efforts and leaves certain regions vulnerable to outbreaks. Additionally, inequitable access can arise from various factors, including economic disparities, geopolitical challenges, supply chain limitations, and intellectual property rights. High-income countries often have better access to vaccines, while lower-income countries struggle to secure an adequate supply. This imbalance not only leads to disparities in healthcare outcomes but also undermines global efforts to control and eradicate viral diseases.

COVID-19 Impact:

The COVID-19 pandemic had an impact on the delivery of health services, particularly immunization programs, all over the world as a fall in vaccination coverage and the overall number of vaccines given was noted. Children missed out on their vaccine doses as a result of this reduction, which reduced the market for these items. Globally, governments made efforts to control the spread by imposing population-wide lockdowns, closing borders, and prohibiting large gatherings. These actions slowed the implementation of numerous initiatives, including vaccine campaigns. Additionally, in order to lessen the effects of COVID-19, the WHO published guidelines for temporarily suspending the activities of mass vaccination programs around the world.

The vials segment is expected to be the largest during the forecast period

The vials segment held the largest share in the market owing to the increasing demand due to its cost effectiveness over prefilled syringes. These small glass or plastic containers provide a sterile environment to preserve the potency and integrity of the vaccine formulations. Vials used in the viral vaccines market are designed to meet stringent quality standards, ensuring the safety and efficacy of the vaccines. However, Vials are specifically chosen for their compatibility with vaccine ingredients, resistance to breakage, and ability to maintain product stability over time. They are typically sealed with rubber stoppers and aluminum caps to prevent contamination and maintain a sterile environment.

The lyophilized segment is expected to have the highest CAGR during the forecast period

During the projection period, the lyophilized segment is expected to have the greatest CAGR. It involves the removal of water from a vaccine formulation through sublimation under low temperature and reduced pressure. The resulting lyophilized viral vaccines are in a solid, dry state, offering several advantages in terms of stability, storage, and transportation. Additionally, lyophilisation helps to extend the shelf life of viral vaccines by reducing degradation and preserving their potency. By removing water, which can contribute to chemical and biological reactions, the lyophilized vaccines exhibit enhanced stability, allowing for longer-term storage without the need for refrigeration.

Region with largest share:

The Asia Pacific region market is estimated to witness the highest share of the global Viral Vaccines market during the forecast period. This is ascribed to elements including the expanding population, rising middle-class discretionary income, and the quick industrialization and urbanization. The expansion of the farm tire sector may also be aided by the region's presence of both small and large-scale manufacturers. Bias farm tires are produced using manufacturing techniques and materials that provide good load capabilities at reasonable prices. Natural rubber is the primary raw material needed to make bias tires. As a result, it is anticipated that the Asia Pacific region's plentiful supply of natural rubber in countries like Thailand, India, Vietnam, Indonesia, China, and Malaysia will increase demand of the market in the region.

Region with highest CAGR:

The North America region is expected to have the highest growth rate over the forecast period. This growth can be attributed high demand for agricultural goods owing to rising living standards, foreign investments and increased consumption. Moreover, growing agricultural industry of countries such as the U.S. and Canada in the region is leading to growing demand for viral vaccines. Along with this, the mechanization in agriculture is also growing in the region, which is also driving the market growth of the North America region.

Key players in the market:

Some of the key players in Viral Vaccines market include: AstraZeneca plc, Emergent BioSolutions Inc., GlaxoSmithKline plc, Merck & Co., Inc., Moderna, Inc., Novartis, Inc., Novavax, Inc., Pfizer, Inc., Sanofi, Seqirus (CSL Limited) and Serum institute of India Private Limited.

Key Developments:

In November 2022, The U.S. FDA granted a Priority Review for GSK's Respiratory Syncytial Virus (RSV) older adult vaccine candidate

In July 2022, CSL SEQIRUS entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute to advance influenza protection and pandemic preparedness

In June 2022, Bavarian Nordic A/S entered into a five-year contract with the government of Canada to procure the IMVAMUNE smallpox vaccine

In July 2021, GSK received US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy

In June 2021, Merck announced the launch of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) in the US, developed in partnership with Sanofi Pasteur

Types Covered:

• Monovalent Vaccines
• Multivalent Vaccines

Forms Covered:

• Liquid
• Lyophilized

Container Formats Covered:

• Vials
• Prefilled Syringes

Biosafety Level Types Covered:

• Biosafety Level 1
• Biosafety Level 2
• Biosafety Level 3
• Biosafety Level 4

Technologies Covered:

• Excluding COVID 19 Vaccines
• Including COVID 19 Vaccine
• Other Technologies

Diseases Covered:

• Influenza
• Pneumococcal Diseases
• Combination Vaccines
• Human Papillomavirus (HPV)
• Herpes Zoster
• Meningococcal Diseases
• Rotavirus
• Measles, Mumps, Rubella (MMR)
• Varicella
• Hepatitis
• Diphtheria, Tetanus And Pertussis (DTP)
• Polio
• COVID-19
• Other Diseases

Age of Administrations Covered:

• Pediatric Vaccine
• Adult Vaccine

Route of Administrations Covered:

• Intramuscular & Subcutaneous Administration
• Oral Administration
• Other Routes Of Administrations

End Users Covered:

• Community Hospitals
• Hospitals
• Specialty Centres
• Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Viral Vaccines Market, By Type

• 5.1 Introduction
• 5.2 Monovalent Vaccines
• 5.3 Multivalent Vaccines

6 Global Viral Vaccines Market, By Form

• 6.1 Introduction
• 6.2 Liquid
• 6.3 Lyophilized

7 Global Viral Vaccines Market, By Container Format

• 7.1 Introduction
• 7.2 Vials
• 7.3 Prefilled Syringes

8 Global Viral Vaccines Market, By Biosafety Level Type

• 8.1 Introduction
• 8.2 Biosafety Level 1
• 8.3 Biosafety Level 2
• 8.4 Biosafety Level 3
• 8.5 Biosafety Level 4

9 Global Viral Vaccines Market, By Technology

• 9.1 Introduction
• 9.2 Excluding COVID 19 Vaccines
  • 9.2.1 Conjugate Vaccines
  • 9.2.2 Inactivated & Subunit Vaccines
  • 9.2.3 Live Attenuated Vaccines
  • 9.2.4 Recombinant Vaccines
  • 9.2.5 Toxoid Vaccines
  • 9.2.6 Viral vector Vaccines
• 9.3 Including COVID 19 Vaccine
  • 9.3.1 Messenger Ribonucleic Acid (mRNA) Vaccines
  • 9.3.2 Viral Vector Vaccines
• 9.4 Other Technologies

10 Global Viral Vaccines Market, By Disease

• 10.1 Introduction
• 10.2 Influenza
• 10.3 Pneumococcal Diseases
• 10.4 Combination Vaccines
• 10.5 Human Papillomavirus (HPV)
• 10.6 Herpes Zoster
• 10.7 Meningococcal Diseases
• 10.8 Rotavirus
• 10.9 Measles, Mumps, Rubella (MMR)
• 10.10 Varicella
• 10.11 Hepatitis
• 10.12 Diphtheria, Tetanus and Pertussis (DTP)
• 10.13 Polio
• 10.14 COVID 19
• 10.15 Other Diseases

11 Global Viral Vaccines Market, By Age of Administration

• 11.1 Introduction
• 11.2 Pediatric Vaccine
• 11.3 Adult Vaccine

12 Global Viral Vaccines Market, By Route of Administration

• 12.1 Introduction
• 12.2 Intramuscular & Subcutaneous Administration
• 12.3 Oral Administration
• 12.4 Other Routes Of Administrations

13 Global Viral Vaccines Market, By End User

• 13.1 Introduction
• 13.2 Community Hospitals
• 13.3 Hospitals
• 13.4 Specialty Centres
• 13.5 Clinics
• 13.6 Other End Users

14 Global Viral Vaccines Market, By Geography

• 14.1 Introduction
• 14.2 North America
  • 14.2.1 US
  • 14.2.2 Canada
  • 14.2.3 Mexico
• 14.3 Europe
  • 14.3.1 Germany
  • 14.3.2 UK
  • 14.3.3 Italy
  • 14.3.4 France
  • 14.3.5 Spain
  • 14.3.6 Rest of Europe
• 14.4 Asia Pacific
  • 14.4.1 Japan
  • 14.4.2 China
  • 14.4.3 India
  • 14.4.4 Australia
  • 14.4.5 New Zealand
  • 14.4.6 South Korea
  • 14.4.7 Rest of Asia Pacific
• 14.5 South America
  • 14.5.1 Argentina
  • 14.5.2 Brazil
  • 14.5.3 Chile
  • 14.5.4 Rest of South America
• 14.6 Middle East & Africa
  • 14.6.1 Saudi Arabia
  • 14.6.2 UAE
  • 14.6.3 Qatar
  • 14.6.4 South Africa
  • 14.6.5 Rest of Middle East & Africa

15 Key Developments

• 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 15.2 Acquisitions & Mergers
• 15.3 New Product Launch
• 15.4 Expansions
• 15.5 Other Key Strategies

16 Company Profiling

• 16.1 AstraZeneca plc
• 16.2 Emergent BioSolutions Inc.
• 16.3 GlaxoSmithKline plc
• 16.4 Merck & Co., Inc.
• 16.5 Moderna, Inc.
• 16.6 Novartis, Inc.
• 16.7 Novavax, Inc.
• 16.8 Pfizer, Inc.
• 16.9 Sanofi
• 16.10 Seqirus (CSL Limited)
• 16.11 Serum institute of India Private Limited